Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of a Medical Alert Tool is Associated with Faster Time to Placement in Contact Precautions in Patients with MDRO Colonization/Infection History.

American journal of infection control·2026
Same author

Neuroimaging Summary Scores Predict Trajectories of Psychotic-Like Experiences in Youth.

medRxiv : the preprint server for health sciences·2026
Same author

Risk Factors Associated with Longitudinal Trajectories of Mania Symptoms in Youth.

medRxiv : the preprint server for health sciences·2026
Same author

Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis.

Molecular psychiatry·2026
Same author

Clinical Applications of Artificial Intelligence in Cardiovascular Imaging: Where Do We Stand?

Life (Basel, Switzerland)·2026
Same author

Heart rate variability in cardiovascular disease diagnosis, prognosis and management.

Frontiers in cardiovascular medicine·2026
Same journal

Severe tricuspid regurgitation is a congestion-driven cardiorenal disease: A longitudinal study defining a right heart failure phenotype.

International journal of cardiology·2026
Same journal

Applicability of ischemic heart disease clinical practice guidelines in low- and middle-income countries.

International journal of cardiology·2026
Same journal

Effectiveness of a new diagnostic algorithm for the diagnosis of unexplained syncope in patients with hypertrophic cardiomyopathy.

International journal of cardiology·2026
Same journal

The predictive role of the FIB-4 index in identifying arrhythmic risk among patients with nonischemic dilated cardiomyopathy.

International journal of cardiology·2026
Same journal

Beyond arrhythmias: Exploring heart failure in arrhythmogenic cardiomyopathy.

International journal of cardiology·2026
Same journal

Corrigendum to "First-in-human study of the K-Clip™ transcatheter annular repair system for severe functional tricuspid regurgitation" [International Journal of Cardiology 390(2023) / IJCA 131174].

International journal of cardiology·2026
See all related articles

Related Experiment Video

Updated: May 30, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Digoxin - time to take the gloves off?

Emma Eade1, Rebecca Cooper, Andrew R J Mitchell

  • 1FY1 Doctor Jersey General Hospital, Jersey, Channel Islands.

International Journal of Cardiology
|August 3, 2011
PubMed
Summary
This summary is machine-generated.

Digoxin is a long-used heart medication, but recent data suggest it may increase mortality and arrhythmias. This review examines outcome data to question its continued use in modern medicine.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Related Experiment Videos

Last Updated: May 30, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Digoxin has a long history of use for atrial fibrillation rate control and heart failure.
  • Despite familiarity, concerns exist regarding digoxin's potential to increase mortality and cause pro-arrhythmia.

Purpose of the Study:

  • To review outcome data associated with digoxin use.
  • To evaluate the continued relevance of digoxin in 21st-century clinical practice.

Main Methods:

  • Literature review of outcome data concerning digoxin.
  • Analysis of studies investigating digoxin's impact on mortality and arrhythmias.

Main Results:

  • Data suggest a potential link between digoxin use and increased mortality.
  • Evidence indicates digoxin may be associated with a higher risk of pro-arrhythmia.

Conclusions:

  • The established benefits of digoxin must be weighed against emerging safety concerns.
  • A critical re-evaluation of digoxin's role in current cardiovascular therapy is warranted.